Madrigal Pharmaceuticals, Inc. (MDGL)

Market Cap	3.88B
Revenue (ttm)	n/a
Net Income (ttm)	-347.34M
Shares Out	19.74M
EPS (ttm)	-19.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,163
Open	191.00
Previous Close	190.94
Day's Range	191.00 - 200.19
52-Week Range	57.21 - 322.67
Beta	-0.70
Analysts	Strong Buy
Price Target	317.22 (+61.34%)
Earnings Date	Nov 6, 2023

About MDGL

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 92
• Stock Exchange: NASDAQ
• Ticker Symbol: MDGL

Analyst Forecast

According to 9 analysts, the average rating for MDGL stock is "Strong Buy." The 12-month stock price forecast is $317.22, which is an increase of 61.34% from the latest price.

Price Target

$317.22

(61.34% upside)

Analyst Consensus: Strong Buy